ZOE.F Zoetis Inc. R
Healthcare · Drug Manufacturers - Specialty & Generic
61.76
-1.37%
Sobre l'empresa
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Rang 52 setmanes
Anàlisi a fons del dividend
Zoetis Inc., a Healthcare sector company specializing in Drug Manufacturers - Specialty & Generic, currently offers a dividend yield of 2.95% in EUR. This yield is significantly above its 5-year average of 0.87% and its 5-year high of 1.35%. Valuation analysis suggests the stock is currently undervalued according to Yield Theory, though its fair value calculation indicates the price is 4.6% above fair value, suggesting a "fair" margin of safety. Momentum and value scores are not available, nor is an overall rating score.
Historial de dividends
Zoetis has a history of consistent dividend increases, maintaining a streak of 12 consecutive years. The company has demonstrated strong dividend growth with a 3-year compound annual growth rate (CAGR) of 15.44% and a 5-year CAGR of 20.11%. Annual dividends per share in EUR have increased steadily: 0.2539 in 2014, 0.3703 in 2017, 0.5783 in 2019, 0.8816 in 2021, 1.1461 in 2022, 1.3224 in 2023, and projected to 1.7632 in 2025. It is recognized as a Dividend Contender.
Seguretat del dividend
The dividend appears well-covered with a payout ratio of 33.77% based on earnings per share. In terms of leverage, Zoetis has a debt-to-equity ratio of 293.996%.
Quantic · Gratis
Llegeix la resta de la seguretat del dividend
A més, els riscos clau i què vigilar tot seguit. Gratis, sense targeta.
Generat per IA a partir de les dades de dividends de Quantic · Actualitzat el 29 Set 2026 · Només informatiu — no és assessorament financer.
Es mostra en anglès — la traducció està en camí.
Historial de preus
Perfil de dividends
Banda de rendibilitat La rendibilitat per dividend actual d'una acció davant del seu propi rang dels últims cinc anys — el mínim, la mitjana i el màxim. A prop del màxim, les accions semblen relativament barates per als ingressos que paguen; a prop del mínim, relativament cares. És la imatge que hi ha darrere de la Teoria del Rendiment per Dividend. Més informació → (5 anys)
Calendari de pagaments
Historial de dividends
Dividend per acció per any
Deute i palanquejament
Últimes xifres del balanç publicades.
seguit per 1
Apareix en aquestes llistes
ZOE.F compleix els criteris d'aquests rànquings de dividends.
Nou en la inversió en dividends?
Només informatiu — no és assessorament financer.
Quantic · Gratis
Segueix ZOE.F i tota la teva cartera
Rendiment real, seguretat del dividend, ingressos nets d'impostos i el teu camí cap a la llibertat — gratis, sense connexió amb el bróker.
Necessites més? El Pro afegeix carteres, seguiment d'ingressos per opcions i més IA. Descobreix el Pro →